Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Free Cash Flow (2023 - 2025)

CG Oncology's Free Cash Flow history spans 3 years, with the latest figure at -$36.2 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 73.34% year-over-year to -$36.2 million; the TTM value through Dec 2025 reached -$132.4 million, down 67.75%, while the annual FY2025 figure was -$132.4 million, 67.75% down from the prior year.
  • Free Cash Flow reached -$36.2 million in Q4 2025 per CGON's latest filing, up from -$39.0 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$8.0 million in Q1 2023 to a low of -$39.0 million in Q3 2025.
  • Average Free Cash Flow over 3 years is -$21.4 million, with a median of -$18.5 million recorded in 2024.
  • Peak YoY movement for Free Cash Flow: crashed 225.87% in 2024, then fell 12.56% in 2025.
  • A 3-year view of Free Cash Flow shows it stood at -$14.6 million in 2023, then crashed by 42.51% to -$20.9 million in 2024, then tumbled by 73.34% to -$36.2 million in 2025.
  • Per Business Quant, the three most recent readings for CGON's Free Cash Flow are -$36.2 million (Q4 2025), -$39.0 million (Q3 2025), and -$27.9 million (Q2 2025).